{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:51:44Z","timestamp":1790506304349,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005010","name":"AIRC","doi-asserted-by":"crossref","award":["173536"],"award-info":[{"award-number":["173536"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s12094-018-1993-2","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T23:08:38Z","timestamp":1542928118000},"page":"845-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Defective levels of both circulating dendritic cells and T-regulatory cells correlate with risk of recurrence in cutaneous melanoma"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4008-4897","authenticated-orcid":false,"given":"M.","family":"Tucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. S.","family":"Stucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mannavola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Passarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"D\u2019Oronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lospalluti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Silvestris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"key":"1993_CR1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.jaad.2018.01.030","volume":"78","author":"E Stiegel","year":"2018","unstructured":"Stiegel E, Xiong D, Ya J, Funchain P, Isakov R, Gastman B, et al. Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma. J Am Acad Dermatol. 2018;78:942\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1993_CR2","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","volume":"25","author":"JE Gershenwald","year":"2018","unstructured":"Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol. 2018;25:2105\u201310 (Springer International Publishing).","journal-title":"Ann Surg Oncol"},{"key":"1993_CR3","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1200\/JCO.2013.50.7681","volume":"32","author":"S Pasquali","year":"2014","unstructured":"Pasquali S, Mocellin S, Mozzillo N, Maurichi A, Quaglino P, Borgognoni L, et al. Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. J Clin Oncol. 2014;32:935\u201341.","journal-title":"J Clin Oncol"},{"key":"1993_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer N, Berking C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757\u201367.","journal-title":"Lancet Oncol"},{"key":"1993_CR5","doi-asserted-by":"publisher","first-page":"000","DOI":"10.1586\/1744666X.2014.955851","volume":"10","author":"M Tucci","year":"2014","unstructured":"Tucci M, Stucci S, Passarelli A, Giudice G, Dammacco F, Silvestris F. The immune escape in melanoma: role of the impaired dendritic cell function. Expert Rev Clin Immunol. 2014;10:000 (Informa UK, Ltd).","journal-title":"Expert Rev Clin Immunol"},{"key":"1993_CR6","doi-asserted-by":"publisher","first-page":"e982382","DOI":"10.4161\/2162402X.2014.982382","volume":"4","author":"I Chevolet","year":"2015","unstructured":"Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, et al. Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. OncoImmunology. 2015;4:e982382 (Taylor & Francis).","journal-title":"OncoImmunology"},{"key":"1993_CR7","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ejso.2017.07.006","volume":"43","author":"S Damude","year":"2017","unstructured":"Damude S, Wevers KP, Murali R, Kruijff S, Hoekstra HJ, Bastiaannet E. A prediction tool incorporating the biomarker S-100B for patient selection for completion lymph node dissection in stage III melanoma. Eur J Surg Oncol. 2017;43:1753\u20139.","journal-title":"Eur J Surg Oncol"},{"key":"1993_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ejso.2015.12.010","volume":"42","author":"S Damude","year":"2016","unstructured":"Damude S, Hoekstra HJ, Bastiaannet E, Muller Kobold AC, Kruijff S, Wevers KP. The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients. Eur J Surg Oncol. 2016;42:545\u201351.","journal-title":"Eur J Surg Oncol"},{"key":"1993_CR9","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1056\/NEJMc1715454","volume":"378","author":"J Weber","year":"2018","unstructured":"Weber J, Qureshi A, Ascierto PA. Adjuvant Therapy in Resected Melanoma. N Engl J Med. 2018;378:680 (Massachusetts Medical Society).","journal-title":"N Engl J Med"},{"key":"1993_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12967-017-1310-9","volume":"15","author":"J Galon","year":"2017","unstructured":"Galon J, Lugli A, Bifulco C, Pages F, Masucci G, Marincola FM, et al. World-wide immunoscore task force: meeting report from the \u201cMelanoma Bridge\u201d, Napoli, November 30th-December 3rd, 2016. J Transl Med. 2017;15:212. \n                    https:\/\/doi.org\/10.1186\/s12967-017-1310-9\n                    \n                  .","journal-title":"J Transl Med."},{"key":"1993_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.canlet.2013.05.013","volume":"337","author":"A Failli","year":"2013","unstructured":"Failli A, Legitimo A, Orsini G, Romanini A, Consolini R. Numerical defect of circulating dendritic cell subsets and defective dendritic cell generation from monocytes of patients with advanced melanoma. Cancer Lett. 2013;337:184\u201392 (Elsevier Ireland Ltd).","journal-title":"Cancer Lett"},{"key":"1993_CR12","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1245\/s10434-007-9488-3","volume":"14","author":"MD McCarter","year":"2007","unstructured":"McCarter MD, Baumgartner J, Escobar GA, Richter D, Lewis K, Robinson W, et al. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol. 2007;14:2854\u201360 (Springer-Verlag).","journal-title":"Ann Surg Oncol"},{"key":"1993_CR13","first-page":"5293","volume":"176","author":"R Houot","year":"2006","unstructured":"Houot R, Perrot I, Garcia E, Durand I, Lebecque S. Human CD4\u2009+\u2009CD25 high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol Am Assoc Immunol. 2006;176:5293\u20138.","journal-title":"J Immunol Am Assoc Immunol"},{"key":"1993_CR14","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0002-9440(10)63238-5","volume":"165","author":"G Gerlini","year":"2004","unstructured":"Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol. 2004;165:1853\u201363.","journal-title":"Am J Pathol"},{"key":"1993_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, et al. Critical role for CD103(+)\/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016;30:324\u201336.","journal-title":"Cancer Cell"},{"key":"1993_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12967-014-0376-x","volume":"13","author":"I Chevolet","year":"2015","unstructured":"Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, et al. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma. J Transl Med. 2015;13:9.","journal-title":"J Transl Med."},{"key":"1993_CR17","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.4161\/hv.29857","volume":"10","author":"A Legitimo","year":"2014","unstructured":"Legitimo A, Consolini R, Failli A, Orsini G, Spisni R. Dendritic cell defects in the colorectal cancer. Hum Vaccin Immunother. 2014;10:3224\u201335.","journal-title":"Hum Vaccin Immunother"},{"key":"1993_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2015.1100791","volume":"5","author":"E Verron\u00e8se","year":"2016","unstructured":"Verron\u00e8se E, Delgado A, Valladeau-Guilemond J, Garin G, Guillemaut S, Tredan O, et al. Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay. OncoImmunology. 2016;5:1\u201315 (Taylor & Francis).","journal-title":"OncoImmunology"},{"key":"1993_CR19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41590-018-0105-3","volume":"19","author":"E Patin","year":"2018","unstructured":"Patin E, Hasan M, Bergstedt J, Rouilly V, Libri V, Urrutia A, et al. Publisher Correction: natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. Nat Immunol. 2018;19:645\u201355 (Nature Publishing Group).","journal-title":"Nat Immunol"},{"key":"1993_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1586\/1744666X.2016.1100965","volume":"12","author":"F Mannavola","year":"2015","unstructured":"Mannavola F, Tucci M, Felici C, Stucci S, Silvestris F. miRNAs in melanoma: a defined role in tumor progression and metastasis. Expert Rev Clin Immunol. 2015;12:79\u201389.","journal-title":"Expert Rev Clin Immunol"},{"key":"1993_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/eci.12363","volume":"45","author":"VC Lombardi","year":"2014","unstructured":"Lombardi VC, Khaiboullina SF, Rizvanov AA. Plasmacytoid dendritic cells, a role in neoplastic prevention and progression. Eur J Clin Invest. 2014;45:1\u20138.","journal-title":"Eur J Clin Invest"},{"key":"1993_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.clim.2007.07.018","volume":"125","author":"G Gerlini","year":"2007","unstructured":"Gerlini G, Urso C, Mariotti G, Di Gennaro P, Palli D, Brandani P, et al. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin Immunol. 2007;125:184\u201393.","journal-title":"Clin Immunol"},{"key":"1993_CR23","doi-asserted-by":"publisher","first-page":"22022","DOI":"10.3390\/ijms141122022","volume":"14","author":"G Orsini","year":"2013","unstructured":"Orsini G, Legitimo A, Failli A, Ferrari P, Nicolini A, Spisni R, et al. Defective generation and maturation of dendritic cells from monocytes in colorectal cancer patients during the course of disease. IJMS. 2013;14:22022\u201341.","journal-title":"IJMS"},{"key":"1993_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1365-2567.2009.03134.x","volume":"128","author":"I Bekeredjian-Ding","year":"2009","unstructured":"Bekeredjian-Ding I, Sch\u00e4fer M, Hartmann E, Pries R, Parcina M, Schneider P, et al. Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. Immunology. 2009;128:439\u201350 (10.1111, Wiley\/Blackwell).","journal-title":"Immunology"},{"key":"1993_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/art.23186","volume":"58","author":"M Tucci","year":"2008","unstructured":"Tucci M, Quatraro C, Lombardi L, Pellegrino C, Dammacco F, Silvestris F. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 2008;58:251\u201362.","journal-title":"Arthritis Rheum"},{"key":"1993_CR26","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/jid.2014.155","volume":"134","author":"J Domizio Di","year":"2014","unstructured":"Di Domizio J, Demaria O, Gilliet M. Plasmacytoid dendritic cells in melanoma: can we revert bad into good? J Invest Dermatol. 2014;134:1797\u2013800.","journal-title":"J Invest Dermatol"},{"key":"1993_CR27","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/jid.2010.24","volume":"130","author":"J Charles","year":"2010","unstructured":"Charles J, Di Domizio J, Salameire D, Bendriss-Vermare N, Aspord C, Muhammad R, et al. Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Dermatol. 2010;130:1646\u201356.","journal-title":"J Invest Dermatol"},{"key":"1993_CR28","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/eji.200323676","volume":"33","author":"M Salio","year":"2003","unstructured":"Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, Smith CL, et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol. 2003;33:1052\u201362 (Wiley-Blackwell).","journal-title":"Eur J Immunol"},{"key":"1993_CR29","doi-asserted-by":"publisher","first-page":"106132","DOI":"10.18632\/oncotarget.22190","volume":"8","author":"A Passarelli","year":"2017","unstructured":"Passarelli A, Mannavola F, Stucci LS, Tucci M, Silvestris F. Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget. 2017;8:106132\u201342.","journal-title":"Oncotarget."},{"key":"1993_CR30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.4161\/cbt.4.5.1780","volume":"4","author":"MR Hussein","year":"2005","unstructured":"Hussein MR. Dendritic cells and melanoma tumorigenesis: an insight. Cancer Biol Ther. 2005;4:501\u20135.","journal-title":"Cancer Biol Ther"},{"key":"1993_CR31","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","volume":"22","author":"KF Bol","year":"2016","unstructured":"Bol KF, Schreibelt G, Gerritsen WR, de Vries IJM, Figdor CG. Dendritic cell-based immunotherapy: state of the art and beyond. Clin Cancer Res Am Assoc Can Res. 2016;22:1897\u2013906.","journal-title":"Clin Cancer Res Am Assoc Can Res"},{"key":"1993_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2017.07.052","volume":"85","author":"CA Gjorup","year":"2017","unstructured":"Gjorup CA, Groenvold M, Hendel HW, Dahlstroem K, Drzewiecki KT, Klausen TW, et al. Health-related quality of life in melanoma patients: impact of melanoma-related limb lymphoedema. Eur J Cancer. 2017;85:122\u201332.","journal-title":"Eur J Cancer"},{"key":"1993_CR33","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ejso.2016.08.007","volume":"43","author":"MF Madu","year":"2017","unstructured":"Madu MF, Wouters MWJM, van Akkooi ACJ. Sentinel node biopsy in melanoma: current controversies addressed. Eur J Surg Oncol. 2017;43:517\u201333.","journal-title":"Eur J Surg Oncol"},{"key":"1993_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1479-5876-11-43","volume":"11","author":"A Mohos","year":"2013","unstructured":"Mohos A, Sebesty\u00e9n T, Liszkay G, Pl\u00f3t\u00e1r V, Horv\u00e1th S, Gaudi I, et al. Immune cell profile of sentinel lymph nodes in patients with malignant melanoma\u2014FOXP3\u2009+\u2009cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome. J Transl Med BioMed Cent. 2013;11:43.","journal-title":"J Transl Med BioMed Cent"},{"key":"1993_CR35","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s00262-007-0286-3","volume":"56","author":"A Lad\u00e1nyi","year":"2007","unstructured":"Lad\u00e1nyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother. 2007;56:1459\u201369 (Springer-Verlag).","journal-title":"Cancer Immunol Immunother"},{"key":"1993_CR36","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813\u201323 (Massachusetts Medical Society).","journal-title":"N Engl J Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-018-1993-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-018-1993-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-018-1993-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T19:14:28Z","timestamp":1574450068000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-018-1993-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["1993"],"URL":"https:\/\/doi.org\/10.1007\/s12094-018-1993-2","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,23]]},"assertion":[{"value":"22 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors disclose financial conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Local Ethic Committee (protocol 4387\/14).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}